Article ; Online: Retrospective Analysis of the Efficacy and Tolerability of Gemcitabine-Based Chemotherapy in Relapsed/Refractory Lymphoma Patients Not Eligible for Stem Cell Transplant.
Clinical lymphoma, myeloma & leukemia
2022 Volume 22, Issue 11, Page(s) 835–840
Abstract: Introduction: Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult ... ...
| Abstract | Introduction: Gemcitabine-based regimens are effective salvage therapy for RR lymphoma patients eligible for ASCT, but there is limited data in transplant-ineligible (TIE) patients. Here, we present a retrospective analysis on the outcome of TIE adult patients with RR lymphoma treated with gemcitabine, cisplatin or carboplatin and dexamethasone (GDP/GDCarboP) +/- rituximab regimen in our center. Patients: We identified 33 patients: 54.5% diffuse large Bcell lymphoma (DLBCL), 6.1% double/triple hit lymphoma, 15% follicular lymphoma, 18% T-cell lymphoma, and 6% classical Hodgkin lymphoma. Majority of the patients had advanced-stage disease and raised LDH at relapse. The cohort's median age was 71 years. The median number of prior lines of treatment was 2, and 60.6% were refractory to their last line of treatment. Results: The overall response rate was 33% (complete response 15%) for the entire cohort and 62.5% for DLBCL patients not refractory to prior line of treatment. At median follow-up of 25 months, the median duration of response and overall survival in the responders were not reached. Conversely, the median overall survival for the non-responders was dismal at 5 months. Fifty-five percent required treatment alteration (dose attenuation or omission and treatment delay for >1 week) due to adverse events, 73% needed transfusion, and 70% had at least 1 hospital admission during treatment. Conclusion: Our real-world data showed that GDP/GDCarboP provides meaningful efficacy and durability, especially among the responders. However, dose modification and inpatient support are frequently needed, indicating the need for good supportive care and close follow-up in this frailer population. |
|---|---|
| MeSH term(s) | Adult ; Humans ; Aged ; Cisplatin/therapeutic use ; Carboplatin/therapeutic use ; Rituximab/therapeutic use ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, B-Cell/drug therapy ; Stem Cell Transplantation ; Lymphoma, Follicular/drug therapy ; Dexamethasone/adverse effects |
| Chemical Substances | gemcitabine (B76N6SBZ8R) ; Cisplatin (Q20Q21Q62J) ; Carboplatin (BG3F62OND5) ; Rituximab (4F4X42SYQ6) ; Dexamethasone (7S5I7G3JQL) |
| Language | English |
| Publishing date | 2022-06-29 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 2540992-X |
| ISSN | 2152-2669 ; 2152-2650 |
| ISSN (online) | 2152-2669 |
| ISSN | 2152-2650 |
| DOI | 10.1016/j.clml.2022.06.010 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 5903: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.